$9.26
2.27% today
Nasdaq, Apr 03, 06:41 pm CET
ISIN
US0453961080
Symbol
ASMB
Sector
Industry

Assembly Biosciences, Inc. Stock price

$9.47
-2.76 22.57% 1M
-5.18 35.36% 6M
-6.31 39.99% YTD
-4.03 29.85% 1Y
-15.97 62.78% 3Y
-177.61 94.94% 5Y
-157.33 94.32% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.08 0.85%
ISIN
US0453961080
Symbol
ASMB
Sector
Industry

Key metrics

Market capitalization $71.06m
Enterprise Value $-37.93m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.74
EV/Sales (TTM) EV/Sales -1.33
P/S ratio (TTM) P/S ratio 2.49
P/B ratio (TTM) P/B ratio 2.12
Revenue growth (TTM) Revenue growth 298.16%
Revenue (TTM) Revenue $28.52m
EBIT (operating result TTM) EBIT $-45.42m
Free Cash Flow (TTM) Free Cash Flow $-51.15m
Cash position $112.08m
EPS (TTM) EPS $-6.72
P/S forward 2.24
EV/Sales forward negative
Short interest 0.38%
Show more

Is Assembly Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Assembly Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Assembly Biosciences, Inc. forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Assembly Biosciences, Inc. forecast:

Buy
67%
Hold
33%

Financial data from Assembly Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
29 29
298% 298%
100%
- Direct Costs 0.13 0.13
71% 71%
0%
28 28
323% 323%
100%
- Selling and Administrative Expenses 18 18
19% 19%
62%
- Research and Development Expense 56 56
14% 14%
196%
-45 -45
29% 29%
-159%
- Depreciation and Amortization 0.13 0.13
71% 71%
0%
EBIT (Operating Income) EBIT -45 -45
30% 30%
-159%
Net Profit -40 -40
34% 34%
-141%

In millions USD.

Don't miss a Thing! We will send you all news about Assembly Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Assembly Biosciences, Inc. Stock News

Neutral
GlobeNewsWire
14 days ago
– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline –
Neutral
GlobeNewsWire
about one month ago
– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will be assessed in addition to safety and pharmacokinetic measures – SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company d...
Neutral
GlobeNewsWire
about one month ago
– ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose –
More Assembly Biosciences, Inc. News

Company Profile

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jason Okazaki
Employees 73
Founded 2005
Website www.assemblybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today